teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 81 Projects Releases Packages Wiki Activity Actions 848
teleo-codex/entities/health/evoke-evoke-plus-trials.md
Teleo Agents 84206b838d
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure 
- Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-03 04:35:32 +00:00

2.5 KiB
Raw Blame History

EVOKE/EVOKE+ Trials

Type: Phase 3 clinical trials
Sponsor: Novo Nordisk
Intervention: Oral semaglutide 14mg (flexible dose)
Indication: Early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid positivity)
Status: Failed (2026)

Trial Design

  • Design: Two parallel Phase 3, double-blind, placebo-controlled trials
  • Population: n=3,808 total, ages 55-85
  • Duration: 104 weeks primary endpoint, 156 weeks extended follow-up
  • Primary endpoints: Cognitive and global decline measures

Results

Primary endpoints: Not met in either trial. Semaglutide did not demonstrate superiority to placebo in slowing cognitive or global decline.

Secondary endpoints:

  • No delay in time to progression to dementia (MCI subgroup, pooled analysis)
  • Biomarker findings: Up to 10% reduction in CSF core AD biomarkers (amyloid, tau)
  • Significant reductions in CSF neuroinflammation markers
  • Critical gap: Biomarker improvements did not translate to clinical benefit

Scientific Interpretation

The biomarker-clinical benefit dissociation suggests three possible explanations:

  1. Dose insufficient to produce clinical effect despite biomarker change
  2. Treatment window too late (early symptomatic disease already past intervention point)
  3. Neuroinflammation/AD pathobiology not rate-limiting in this population

Implications

For GLP-1 CNS expansion: Establishes mechanism specificity boundary. Semaglutide shows efficacy in addiction (VTA dopamine pathways) but not neurodegeneration (amyloid/tau pathways), indicating GLP-1 CNS effects are pathway-specific rather than universally neuroprotective.

For Alzheimer's drug development: Adds to evidence that biomarker improvement (even in core AD pathology markers) does not guarantee clinical benefit, raising questions about surrogate endpoint validity.

For prevention vs. treatment: May indicate GLP-1 has preventive rather than therapeutic value in neurodegeneration, requiring different trial design in at-risk populations.

Timeline

  • 2026-04-15 — Results published in The Lancet
  • 2026-04 — Novo Nordisk announces discontinuation of 1-year extension periods for both trials

Sources

  • The Lancet (2026): "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials"
  • Alzheimer's Drug Discovery Foundation analysis
  • NeurologyLive coverage